A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy

Summary

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness/wakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.

Timeline

Start

2026-06-04

Primary completion

2027-10

Completion

2027-11

Drugs

Indications